Premium
PharmVar GeneFocus: CYP3A5
Author(s) -
RodriguezAntona Cristina,
Savieo Jessica L.,
Lauschke Volker M.,
Sangkuhl Katrin,
Drögemöller Britt I.,
Wang Danxin,
Schaik Ron H. N.,
Gilep Andrei A.,
Peter Arul P.,
Boone Erin C.,
Ramey Bronwyn E.,
Klein Teri E.,
WhirlCarrillo Michelle,
Pratt Victoria M.,
Gaedigk Andrea
Publication year - 2022
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.2563
Subject(s) - pharmacogenomics , cyp3a5 , pharmacogenetics , allele , locus (genetics) , tacrolimus , biology , genetics , computational biology , medicine , gene , transplantation , genotype
The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Variable CYP3A5 activity is of clinical importance regarding tacrolimus metabolism. This GeneFocus provides a CYP3A5 gene summary with a focus on aspects regarding standardized nomenclature. In addition, this review also summarizes recent changes and updates, including the retirement of several allelic variants and provides an overview of how PharmVar CYP3A5 star allele nomenclature is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).